Trial reportAllergy2015
Determinants of efficacy and safety in epicutaneous allergen immunotherapy: summary of three clinical trials.
Trial report in Allergy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 83 citations in OpenAlex.
- Demonstration of Gliadin Penetration into the Epidermis by Tape Stripping as Prerequisite for Percutaneous Sensitisation in Wheat Allergy.International journal of molecular sciences · 2026Article
- Microneedles in Allergy Immunotherapy: the Present and Future.Current allergy and asthma reports · 2025Review
- Carbamylated monomeric allergoids for sublingual immunotherapy in pediatric respiratory allergies.Asia Pacific allergy · 2025Review
- Review
- Novel Approaches to Allergen Immunotherapy for Respiratory Allergies.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Sustained antigens delivery using composite microneedles for effective epicutaneous immunotherapy.Drug delivery and translational research · 2023Article
- Innovative delivery systems for epicutaneous immunotherapy.Frontiers in immunology · 2023Review
- Chinese Guideline on Allergen Immunotherapy for Allergic Rhinitis: The 2022 Update.Allergy, asthma & immunology research · 2022Review
- Targeted allergen-specific immunotherapy within the skin improves allergen delivery to induce desensitization to peanut.Immunotherapy · 2022Article
- Recent Advances in Allergen-Specific Immunotherapy in Humans: A Systematic Review.Immune network · 2022Review
- Review
- AIT: New Avenues in Allergen Immunotherapy.Handbook of experimental pharmacology · 2022Article
- Evaluation of a Novel Adjuvanted Vaccine for Ultrashort Regimen Therapy ofFrontiers in immunology · 2022Article
- [The route is the destination-novel forms of application of allergen immunotherapy].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2021Review
- Innovative Systems to Deliver Allergen Powder for Epicutaneous Immunotherapy.Frontiers in immunology · 2021Review
- Review
- Article
- Allergic Rhinitis: What Do We Know About Allergen-Specific Immunotherapy?Frontiers in allergy · 2021Review
- EAACI Allergen Immunotherapy User's Guide.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2020Review
- Loricrin: Past, Present, and Future.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The results of our third trial on epicutaneous allergen-specific immunotherapy (EPIT) will be presented and discussed in the context of our previous trials. This monocentric, placebo-controlled, double-blind phase I/IIa trial included 98 patients with grass pollen rhinoconjunctivitis. Prior to the pollen season 2009, patients received six patches (allergen extract: n = 48; placebo: n = 50) with weekly intervals, administered onto tape-stripped skin. Allergen EPIT produced a median symptom improvement of 48% in 2009 and 40% in the treatment-free follow-up year 2010 as compared to 10% and 15% improvement after placebo EPIT (P = 0.003). After allergen EPIT but not placebo EPIT, conjunctival allergen reactivity was significantly decreased and allergen-specific IgG4 responses were significantly elevated (P < 0.001). In conclusion, our three EPIT trials found that allergen EPIT can ameliorate hay fever symptoms. Overall, treatment efficacy appears to be determined by the allergen dose. Local side-effects are determined by the duration of patch administration, while risk of systemic allergic side-effects is related to the degree of stratum corneum disruption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.